Salma Hassan

Hu Wang, Salma Hassan, Yuyuan Liu et al.

In multi-modal learning, some modalities are more influential than others, and their absence can have a significant impact on classification/segmentation accuracy. Addressing this challenge, we propose a novel approach called Meta-learned Modality-weighted Knowledge Distillation (MetaKD), which enables multi-modal models to maintain high accuracy even when key modalities are missing. MetaKD adaptively estimates the importance weight of each modality through a meta-learning process. These learned importance weights guide a pairwise modality-weighted knowledge distillation process, allowing high-importance modalities to transfer knowledge to lower-importance ones, resulting in robust performance despite missing inputs. Unlike previous methods in the field, which are often task-specific and require significant modifications, our approach is designed to work in multiple tasks (e.g., segmentation and classification) with minimal adaptation. Experimental results on five prevalent datasets, including three Brain Tumor Segmentation datasets (BraTS2018, BraTS2019 and BraTS2020), the Alzheimer's Disease Neuroimaging Initiative (ADNI) classification dataset and the Audiovision-MNIST classification dataset, demonstrate the proposed model is able to outperform the compared models by a large margin. The code is available at https://github.com/billhhh/MetaKD.

Salma Hassan, Hamad Al Hammadi, Ibrahim Mohammed et al.

The early detection and nuanced subtype classification of non-small cell lung cancer (NSCLC), a predominant cause of cancer mortality worldwide, is a critical and complex issue. In this paper, we introduce an innovative integration of multi-modal data, synthesizing fused medical imaging (CT and PET scans) with clinical health records and genomic data. This unique fusion methodology leverages advanced machine learning models, notably MedClip and BEiT, for sophisticated image feature extraction, setting a new standard in computational oncology. Our research surpasses existing approaches, as evidenced by a substantial enhancement in NSCLC detection and classification precision. The results showcase notable improvements across key performance metrics, including accuracy, precision, recall, and F1-score. Specifically, our leading multi-modal classifier model records an impressive accuracy of 94.04%. We believe that our approach has the potential to transform NSCLC diagnostics, facilitating earlier detection and more effective treatment planning and, ultimately, leading to superior patient outcomes in lung cancer care.

Salma Hassan, Dawlat Akaila, Maryam Arjemandi et al.

In the complex realm of cognitive disorders, Alzheimer's disease (AD) and vascular dementia (VaD) are the two most prevalent dementia types, presenting entangled symptoms yet requiring distinct treatment approaches. The crux of effective treatment in slowing neurodegeneration lies in early, accurate diagnosis, as this significantly assists doctors in determining the appropriate course of action. However, current diagnostic practices often delay VaD diagnosis, impeding timely intervention and adversely affecting patient prognosis. This paper presents an innovative multi-omics approach to accurately differentiate AD from VaD, achieving a diagnostic accuracy of 89.25%. The proposed method segments the longitudinal MRI scans and extracts advanced radiomics features. Subsequently, it synergistically integrates the radiomics features with an ensemble of clinical, cognitive, and genetic data to provide state-of-the-art diagnostic accuracy, setting a new benchmark in classification accuracy on a large public dataset. The paper's primary contribution is proposing a comprehensive methodology utilizing multi-omics data to provide a nuanced understanding of dementia subtypes. Additionally, the paper introduces an interpretable model to enhance clinical decision-making coupled with a novel model architecture for evaluating treatment efficacy. These advancements lay the groundwork for future work not only aimed at improving differential diagnosis but also mitigating and preventing the progression of dementia.

Numan Saeed, Salma Hassan, Shahad Hardan et al.

We present a publicly available multimodal dataset for head and neck cancer research, comprising 1123 annotated Positron Emission Tomography/Computed Tomography (PET/CT) studies from patients with histologically confirmed disease, acquired from 10 international medical centers. All studies contain co-registered PET/CT scans with varying acquisition protocols, reflecting real-world clinical diversity from a long-term, multi-institution retrospective collection. Primary gross tumor volumes (GTVp) and involved lymph nodes (GTVn) were manually segmented by experienced radiation oncologists and radiologists following established guidelines. We provide anonymized NifTi files, expert-annotated segmentation masks, comprehensive clinical metadata, and radiotherapy dose distributions for a patient subset. The metadata include TNM staging, HPV status, demographics, long-term follow-up outcomes, survival times, censoring indicators, and treatment information. To demonstrate its utility, we benchmark three key clinical tasks: automated tumor segmentation, recurrence-free survival prediction, and HPV status classification, using state-of-the-art deep learning models like UNet, SegResNet, and multimodal prognostic frameworks.

Ahmed Sharshar, Yasser Ashraf, Tameem Bakr et al.

Alzheimer's disease affects over 55 million people worldwide and is projected to more than double by 2050, necessitating rapid, accurate, and scalable diagnostics. However, existing approaches are limited because they cannot achieve clinically acceptable accuracy, generalization across datasets, robustness to missing modalities, and explainability all at the same time. This inability to satisfy all these requirements simultaneously undermines their reliability in clinical settings. We propose OmniBrain, a multimodal framework that integrates brain MRI, radiomics, gene expression, and clinical data using a unified model with cross-attention and modality dropout. OmniBrain achieves $92.2 \pm 2.4\%$accuracy on the ANMerge dataset and generalizes to the MRI-only ADNI dataset with $70.4 \pm 2.7\%$ accuracy, outperforming unimodal and prior multimodal approaches. Explainability analyses highlight neuropathologically relevant brain regions and genes, enhancing clinical trust. OmniBrain offers a robust, interpretable, and practical solution for real-world Alzheimer's diagnosis.